1. HBW Insight
  2. >>Geography
  3. >>North America
  4. >>United States

FDA Action Items For CBD Policy? The List Is Short Due To 'Critical' Data Gaps

 
• By Malcolm Spicer

FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."

Macro texture of old Wooden box catalog with cobwebs and mold

The Food and Drug Administration’s agenda for developing a policy on cannabidiol use in dietary supplements and other non-drug products includes two reports due to Congress within six months. After those action items, however, the list is bare.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America